van den Meiracker A H, Man in't Veld A J, Boomsma F, Fischberg D J, Molinoff P B, Schalekamp M A
Department of Internal Medicine I, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands.
Circulation. 1989 Oct;80(4):903-14. doi: 10.1161/01.cir.80.4.903.
In an attempt to further clarify the mechanism of the maintenance of the antihypertensive effect of beta-adrenoceptor antagonists, the effects of four antagonists with different ancillary properties (acebutolol, atenolol, pindolol, and propranolol) on systemic and renal hemodynamics, body fluid volumes, hormones, and lymphocyte beta-adrenoceptor density were studied in four groups of 10 hypertensive patients. The patients were observed for 3 weeks during active treatment and for 2 weeks after withdrawal of treatment. At the end of the 3-week treatment period, the four drugs had an equal antihypertensive effect (fall in mean arterial pressure, 10-13%). Although renin activity was suppressed (60-70%) by all four drugs, changes in renin or pretreatment values of renin levels were not correlated with the fall in blood pressure. The drugs had no effect on plasma catecholamine concentrations or body fluid volumes. Despite similar antihypertensive effects among the four drugs, the changes in flow and resistance underlying the fall in blood pressure differed considerably. With pindolol, the fall in blood pressure was associated with a fall in vascular resistance (26 +/- 6%), whereas with propranolol, it was predominantly associated with a fall in cardiac output (11 +/- 7%). No significant changes in vascular resistance or cardiac output occurred with atenolol or acebutolol. The changes in renal blood flow and renal vascular resistance occurred in parallel with the changes in cardiac output and systemic vascular resistance. Plasma epinephrine concentration and pretreatment cardiac chronotropic responsiveness to isoproterenol appeared to be inversely correlated with lymphocyte beta-adrenoceptor density (Bmax) (r = -0.41 and -0.43, respectively). With pindolol, Bmax decreased maximally by 39 +/- 6%, and with propranolol, it increased by 51 +/- 17%. With both drugs, significant changes in Bmax were already present 24 hours after treatment. Furthermore, 1 week after withdrawal of treatment with pindolol, Bmax was still down-regulated, and cardiac chronotropic responsiveness was still decreased, whereas 1 week after withdrawal of propranolol, Bmax was still up-regulated, and cardiac chronotropic responsiveness was still increased. No changes in Bmax occurred with the beta 1-selective antagonists acebutolol and atenolol. Thus, despite an equal antihypertensive effect, the four beta-adrenoceptor antagonists appear to have dissimilar effects on cardiac output, renal blood flow, and lymphocyte beta-adrenoceptors. Changes in cardiac output, the circulating blood volume, or angiotensin-mediated vasoconstriction are factors unlikely to be crucial for the antihypertensive effect of beta-adrenoceptor antagonists. Therefore, interference with vasoconstrictor nerve activity through blockade of either central or peripheral prejunctional beta-adrenoceptors could be an alternative explanation of their blood pressure-lowering potential.
为了进一步阐明β肾上腺素受体拮抗剂维持降压作用的机制,我们在四组每组10例高血压患者中研究了四种具有不同辅助特性的拮抗剂(醋丁洛尔、阿替洛尔、吲哚洛尔和普萘洛尔)对全身和肾脏血流动力学、体液容量、激素以及淋巴细胞β肾上腺素受体密度的影响。患者在积极治疗期间观察3周,治疗停药后观察2周。在3周治疗期结束时,这四种药物具有相同的降压效果(平均动脉压下降10 - 13%)。尽管这四种药物均抑制肾素活性(60 - 70%),但肾素变化或肾素水平的治疗前值与血压下降无关。这些药物对血浆儿茶酚胺浓度或体液容量无影响。尽管这四种药物的降压效果相似,但血压下降背后的血流和阻力变化差异很大。使用吲哚洛尔时,血压下降与血管阻力下降(26±6%)相关,而使用普萘洛尔时,主要与心输出量下降(11±7%)相关。阿替洛尔或醋丁洛尔使用时,血管阻力或心输出量无显著变化。肾血流量和肾血管阻力的变化与心输出量和全身血管阻力的变化平行。血浆肾上腺素浓度和治疗前心脏对异丙肾上腺素的变时反应性似乎与淋巴细胞β肾上腺素受体密度(Bmax)呈负相关(r分别为 - 0.41和 - 0.43)。使用吲哚洛尔时,Bmax最大下降39±6%,使用普萘洛尔时,Bmax增加51±17%。使用这两种药物时,治疗24小时后Bmax就已出现显著变化。此外,停用吲哚洛尔治疗1周后,Bmax仍下调,心脏变时反应性仍降低,而停用普萘洛尔1周后,Bmax仍上调,心脏变时反应性仍增加。β1选择性拮抗剂醋丁洛尔和阿替洛尔使用时Bmax无变化。因此,尽管降压效果相同,但这四种β肾上腺素受体拮抗剂对心输出量、肾血流量和淋巴细胞β肾上腺素受体的影响似乎不同。心输出量、循环血容量或血管紧张素介导的血管收缩变化不太可能是β肾上腺素受体拮抗剂降压作用的关键因素。因此,通过阻断中枢或外周突触前β肾上腺素受体来干扰血管收缩神经活动可能是其降压潜力的另一种解释。